On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons

Annals of the New York Academy of Sciences

Volumn 1074, Issue , 2006, Pages 320-329

  Geracitano, Raffaella ^a   Federici, Mauro ^a   Bernardi, Giorgio ^a,b   Mercuri, Nicola B ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Amineptine; Amphetamine; Cocaine; Dopamine; Ecstasy; Levodopa; Methylphenidate; Nomifensine; Trace amines

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINEPTINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; LEVODOPA; META TYRAMINE; METHYLPHENIDATE; NOMIFENSINE; PHENETHYLAMINE; PSYCHOSTIMULANT AGENT;

ANIMAL CELL; CONFERENCE PAPER; DENDRITE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFECT; MESENCEPHALON; NERVE ENDING; NONHUMAN; RAT; RECEPTOR UPREGULATION;

EID: 33749551468     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1369.029     Document Type: Conference Paper

References (45)

1. GIROS, B. & M.G. CARON. 1993. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14: 43-49.
2. DI CHIARA, G. & A. IMPERATO. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85: 5274-5278.
3. SEEMAN, P. & H.B. NIZNIK. 1990. Dopamine receptors and transporters in Parkin-son's disease and schizophrenia. FASEB J. 4: 2737-2744.
4. MERCURI, N.B., P. CALABRESI & G. BERNARDI. 1992. The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci. 51: 711-718.
5. HUNT, R.D. et al. 1984. Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity. Life Sci. 35: 885-897.
6. KOOB, G.F. & E.J. NESTLER. 1997. The neurobiology of drug addiction. J. Neuropsychiatry Clin. Neurosci. 9: 482-497.
7. GERACITANO, R. et al. 2004. Inhibitory effects of trace amines on rat midbrain dopaminergic neurons. Neuropharmacology 46: 807-814.
8. SKERRITT, J.H. et al. 2000. Development of immunoassays for tyramine and tryptamine toxins of Phalaris aquatica L. J. Agric. Food Chem. 48: 27-32.
9. MERCURI, N.B., P. CALABRESI & G. BERNARDI. 1989. The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro. Br. J. Pharmacol. 98: 127-134.
10. MERCURI, N.B. et al. 1991. Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system. Br. J. Pharmacol. 104: 700-704.
11. LACEY, M.G., N.B. MERCURI & R.A. NORTH. 1990. Actions of cocaine on rat dopaminergic neurones in vitro. Br. J. Pharmacol. 99: 731-735.
12. MERCURI, N.B. et al. 1991. Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. Neurosci. Lett. 131: 145-148.
13. FEDERICI, M. et al. 2005. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol. Psychiatry 57: 361-365.
14. MERCURI, N.B., P. CALABRESI & G. BERNARDI. 1990. Responses of rat substantia nigra compacta neurones to L-DOPA. Br. J. Pharmacol. 100: 257-260.
15. MERCURI, N.B., P. CALABRESI & G. BERNARDI. 1991. Dopamine uptake inhibition potentiates the effects of L-DOPA on rat substantia nigra zona compacta neurons. Neurosci. Lett. 126: 79-82.
16. MERCURI, N.B. & G. BERNARDI. 2005. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 26: 341-344.
17. IVERSEN, L.L. 1971. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41: 571-591.
18. AMARA, S.G. et al. 1998. Molecular physiology and regulation of catecholamine transporters. Adv. Pharmacol. 42: 164-168.
19. AMARA, S.G. & M.S. SONDERS. 1998. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51: 87-96.
20. INGRAM, S.L., B.M. PRASAD & S.G. AMARA. 2002. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat. Neurosci. 5:971-978.
21. SULZER, D. & A. GALLI. 2003. Dopamine transport currents are promoted from curiosity to physiology. Trends Neurosci. 26: 173-176.
22. SOTNIKOVA, T.D. et al. 2006. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol. Disord. Drug Targets 5: 45-56.
23. CAMERON, D.L. & J.T. WILLIAMS. 1994. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J. Neurosci. 14: 6763-6767.
24. JOHNSON, S.W., N.B. MERCURI & R.A. NORTH. 1992. 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J. Neurosci. 12: 2000-2006.
25. TALBOT, P.S. & M. LARUELLE. 2002. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. 12: 503-511.
26. RUDNICK, G. & J. CLARK. 1993. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta 1144: 249-263.
27. RAITERI, M. et al. 1979. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208: 195-202.
28. SCARPONI, M., G. BERNARDI & N.B. MERCURI. 1999. Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons. Eur. J. Neurosci. 11: 593-598.
29. LINDEMANN, L. & M.C. HOENER. 2005. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 26: 274-281.
30. PALADINI, C.A. et al. 2001. Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons. Nat. Neurosci. 4: 275-281.
31. MUNDORP, M.L., S.E. HOCHSTETLER & R.M. WIGHTMAN. 1999. Amine weak bases disrupt vesicular storage and promote exocytosis in chromaffin cells. J. Neurochem. 73: 2397-2405.
32. JANSSEN, P.A. et al. 1999. Does phenylethylamine act as an endogenous amphetamine in some patients? Int. J. Neuropsychopharmacol. 2: 229-240.
33. SORA, I. et al. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98: 5300-5305.
34. HARRIS, G.C., K. ALTOMARE & G. ASTON-JONES. 2001. Preference for a cocaine-associated environment is attenuated by augmented accumbal serotonin in cocaine withdrawn rats. Psychopharmacology (Berl). 156: 14-22.
35. FLECKENSTEIN, A.E. & G.R. HANSON. 2003. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 479: 283-289.
36. GREEN, A.R. et al. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55: 463-508.
37. GOLDMAN, D., G. OROSZI & F. DUCCI. 2005. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 6: 521-532.
38. VOLKOW, N.D. et al. 1999. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 65: PL7-PL12.
39. STEINER, I. & I. WIRGUIN. 2003. Levodopa addiction in non-parkinsonian patients. Neurology 61: 1451-1453.
40. MERIMS, D., R. GALILI-MOSBERG & E. MELAMED. 2000. Is there addiction to levodopa in patients with Parkinson's disease?. Mov. Disord. 15: 1014-1016.
41. HADDAD, P. 1999. Do antidepressants have any potential to cause addiction? J. Psychopharmacol. 13: 300-307.
42. STANSFIELD, K.H. & C.L. KIRSTEIN. 2005. Neurochemical effects of cocaine in adolescence compared to adulthood. Brain Res. Dev. Brain Res. 159: 119-125.
43. KELLEY, A.E., C.A. SCHILTZ & C.F. LANDRY. 2005. Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol. Behav. 86: 11-14.
44. WESTERMEYER, J. 1999. The role of cultural and social factors in the cause of addictive disorders. Psychiatr. Clin. North Am. 22: 253-273.
45. ROBINSON, I.E. & K.C. BERRIDGE. 2000. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95(Suppl 2): S91-S117.